EUVIMEDEUVIMED entdecken
Crossref

Inhibition of YAP/TAZ pathway contributes to the cytotoxicity of silibinin in MCF-7 and MDA-MB-231 human breast cancer cells

Jianing Fu, Weiwei Liu, Siyu Liu, Ruxiao Zhao, Toshihiko Hayashi, Haina Zhao, Yinlanqi Xiang, Kazunori Mizuno, Shunji Hattori, Hitomi Fujisaki, Takashi Ikejima

Cellular Signalling · 2024

DOI: 10.1016/j.cellsig.2024.111186 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cellular Signalling, 2024. Verfasst von Jianing Fu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Silybin, Transcriptional Coactivator with PDZ-Binding Motif Proteins, YAP-Signaling Proteins. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: Shenyang Pharmaceutical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer is one of the most common cancers threatening women's health. Our previous study found that silibinin induced the death of MCF-7 and MDA-MB-231 human breast cancer cells. We noticed that silibinin-induced cell damage was accompanied by morphological changes, including the increased cell aspect ratio (cell length/width) and decreased cell area. Besides, the cytoskeleton is also destroyed in cells treated with silibinin. YAP/TAZ, a mechanical signal sensor interacted with extracellular pressure, cell adhesion area and cytoskeleton, is also closely associated with cell survival, proliferation and migration. Thus, the involvement of YAP/TAZ in the cytotoxicity of silibinin in breast cancer cells has attracted our interests. Excitingly, we find that silibinin inhibits the nuclear translocation of YAP/TAZ in MCF-7 and MDA-MB-231 cells, and reduces the mRNA expressions of YAP/TAZ target genes, ACVR1, MnSOD and ANKRD. More importantly, expression of YAP1 gene is negatively correlated with the survival of the patients with breast cancers. Molecular docking analysis reveals high probabilities for binding of silibinin to the proteins in the YAP pathways. DARTS and CETSA results confirm the binding abilities of silibinin to YAP and LATS. Inhibiting YAP pathway either by addition of verteporfin, an inhibitor of YAP/TAZ-TEAD, or by transfection of si-RNAs targeting YAP or TAZ further enhances silibinin-induced cell damage. While enhancing YAP activity by silencing LATS1/2 or overexpressing YAPS127/397A, an active form of YAP, attenuates silibinin-induced cell damage. These findings demonstrate that inhibition of the YAP/TAZ pathway contributes to cytotoxicity of silibinin in breast cancers, shedding lights on YAP/TAZ-targeted cancer therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsSilybinTranscriptional Coactivator with PDZ-Binding Motif ProteinsYAP-Signaling ProteinsFemaleHumansAdaptor Proteins, Signal TransducingCell Line, TumorCell ProliferationCell SurvivalGene Expression Regulation, NeoplasticIntracellular Signaling Peptides and ProteinsMCF-7 CellsMolecular Docking SimulationPhosphoproteinsSignal TransductionTrans-ActivatorsTranscription FactorsVerteporfin

Stichwörter der Autor:innen

Breast cancersCell morphologyLATSSilibininYAP/TAZ

Substanzen

Adaptor Proteins, Signal TransducingIntracellular Signaling Peptides and ProteinsPhosphoproteinsSilybinTrans-ActivatorsTranscription FactorsTranscriptional Coactivator with PDZ-Binding Motif ProteinsVerteporfinWWTR1 protein, humanYAP-Signaling Proteins

Autor:innen und Institutionen

  • Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, China.
  • Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, China; Nippi Research Institute of Biomatrix, Toride, Ibaraki 302-0017, Japan.
  • Nippi Research Institute of Biomatrix, Toride, Ibaraki 302-0017, Japan.
  • Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, China; Key Laboratory of Computational Chemistry-Based Natural Antitumor Drug Research & Development, Liaoning, China. Electroni…

Förderung

  • Shenyang Pharmaceutical University

Zitieren

APA

Fu, J., Liu, W., Liu, S., Zhao, R., Hayashi, T., Zhao, H., Xiang, Y., Mizuno, K., Hattori, S., Fujisaki, H., & Ikejima, T. (2024). Inhibition of YAP/TAZ pathway contributes to the cytotoxicity of silibinin in MCF-7 and MDA-MB-231 human breast cancer cells. Cellular Signalling. https://doi.org/10.1016/j.cellsig.2024.111186

Vancouver

Fu J, Liu W, Liu S, Zhao R, Hayashi T, Zhao H, et al. Inhibition of YAP/TAZ pathway contributes to the cytotoxicity of silibinin in MCF-7 and MDA-MB-231 human breast cancer cells. Cellular Signalling. 2024. doi:10.1016/j.cellsig.2024.111186

BibTeX
@article{Fu2024,
  author = {Fu, Jianing and Liu, Weiwei and Liu, Siyu and Zhao, Ruxiao and Hayashi, Toshihiko and Zhao, Haina and Xiang, Yinlanqi and Mizuno, Kazunori and Hattori, Shunji and Fujisaki, Hitomi and Ikejima, Takashi},
  title = {Inhibition of YAP/TAZ pathway contributes to the cytotoxicity of silibinin in MCF-7 and MDA-MB-231 human breast cancer cells},
  journal = {Cellular Signalling},
  year = {2024},
  doi = {10.1016/j.cellsig.2024.111186}
}
Kostenlos starten →